ReGenTree, LLC

Industry · 7 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 Neurotrophic Keratopathy	Phase 3	2023-04-11
Completed	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 Dry Eye Syndromes, Dry Eye	Phase 3	2019-05-24
Completed	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 Dry Eye Syndrome	Phase 3	2016-11-01
Terminated	Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEE Neurotrophic Keratopathy	Phase 3	2015-09-17
Completed	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 Dry Eye Syndrome	Phase 2 / Phase 3	2015-09-01
Completed	Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye Dry Eye Syndrome, Dry Eye	Phase 2	2011-08-01
Terminated	A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds Diabetes	Phase 2	2007-12-01